Treatment
Savolitinib clinical trials
We’re tracking 5 recruiting studies that include Savolitinib, each written for real people, not researchers, below.
Recruiting studies
- NCT07322783RecruitingPhase 2
Osimertinib plus savolitinib for resistant lung cancer
This trial tests a combination of two targeted drugs (osimertinib and savolitinib) for people with a specific type of advanced non-small cell lung cancer that has stopped responding to standard treatments. It may help patients whose cancer has a low number of MET gene copies.
QingdaoAges 18–80 - NCT05620628RecruitingPhase 2
Test savolitinib plus durvalumab for MET-amplified stomach cancer
This trial studies whether blocking MET (a cancer growth signal) with savolitinib, combined with durvalumab (an immune treatment), can shrink advanced gastric (stomach) cancer that has worsened after chemotherapy. It may help people whose tumors have MET amplification and measurable disease that can be tracked on scans.
SeoulAges 19 years+ - NCT05777278RecruitingPhase 1/Phase 2
Savolitinib plus docetaxel for advanced lung cancer with high MET
This trial studies savolitinib (an oral MET-targeted medicine) combined with docetaxel (an IV chemotherapy) in people with advanced non-small cell lung cancer (NSCLC) whose tumor has high MET activity. It’s designed to see if this combination can shrink tumors or control the cancer after the first standard treatment.
Guangzhou, GuangdongAges 18 years+ - NCT04322890RecruitingPhase 2
Study for advanced lung cancer with gene mutations
This Phase 2 trial studies treatment strategies for people with stage IV non-small cell lung cancer (NSCLC) who have certain cancer gene mutations (like EGFR, ALK, or ROS1). It aims to see how different treatments affect survival and tumor response.
Changsha, HunanAges 18 years+ - NCT06563999RecruitingPhase 2
Study of new drugs for stage III lung cancer with rare gene changes
This trial tests whether giving treatment before surgery (neoadjuvant therapy) can help people with stage III lung cancer that has certain rare gene changes. The goal is to see if this approach can shrink the tumor enough to allow surgery.
Guangzhou, GuangdongAges 18–75
What Savolitinib is being studied for
Conditions with recruiting Savolitinib studies.
Common questions
- Are there clinical trials studying Savolitinib?
- Yes. Clin2 currently lists 5 recruiting studies that include Savolitinib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Savolitinib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Savolitinib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Savolitinib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.